Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS Telehealth Demo Supports Health Buddy As Aid To Chronic Care Coordination

This article was originally published in The Gray Sheet

Executive Summary

After analyzing a 2006-2007 CMS demonstration project on the integration of telehealth technology with chronic care management services, a Stanford University researcher says the cost savings were significant enough to merit a closer look.

You may also be interested in...



Digital Health In Brief

Bosch Healthcare backs digital learning lab in UK. Vanguard Health partners with AirStrip. More briefs.

Health Hero Network

Internet-based health care management concern receives FDA clearance for blood glucose meter connectivity with its Health Buddy appliance to collect biometric data obtained from blood glucose meters and to transmit it via the Internet to the patient's physician, the firm announces Dec. 2. Part of the firm's Health Hero communications platform, which is used at home by patients to receive and respond to reminders and questions from their providers, the Health Buddy is the first biometric data collection and transmission system cleared by FDA

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT030515

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel